Aligning Incentives for Antibiotic Development and Use with Public Health Needs
The number of companies researching antibiotics has fallen drastically in the last 20 years and few new antibiotics have been developed. Apart from the poor economic return, there are particular scientific challenges in developing antibiotics. And companies complain that regulatory requirements are uncoordinated and disproportionate, and correspondingly costly, which compounds the problem of inadequate returns. Moreover, there is a need to provide incentives to combat inappropriate use of antibiotics.
Participants at this high-level roundtable will discuss how to move forward with politically feasible schemes to incentivize drug development and more appropriate use of antibiotics.
Attendance at this event is by invitation only.